MPH Health Care AG
MPH Mittelständische Pharma Holding AG: IFRS results Q1 2015, sales of EUR 52.75 million, net income of EUR 1.26 million
MPH Mittelständische Pharma Holding AG / Key word(s): Quarter Results/Development of Sales IFRS results Q1 2015, sales of EUR 52.75 million, net income of EUR 1.26 million MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its IFRS Group results for the first quarter of 2015. In the first quarter 2015 the MPH Group achieved sales of EUR 52.75 million (prior-year period: EUR 56.17 million). Net profit for the period was EUR 1.26 million (prior-year period: EUR 2.95 million). In the pharma segment (HAEMATO AG) sales and net profit were below the level of the previous year period. From July 2014 to April 2015 tightenings in the pharmaceutical regulations led to a considerable reduction of the stock turn rate. For the period from May to December 2015 we are confident, that HAMEATO will reach good results. In good time to the lifting of the tightenings of the pharmaceutical regulations HAEMATO has doubled the production capacities. HAEMATO has the capacities to catch up, which was achieved less in the first quarter 2015. In the field of medical aesthetics (M1 Med Beauty AG) an admission for the hospital at the Berlin location has been issued. With immediate effect the M1 Med Beauty Berlin GmbH is able to expand its market share with 40 % higher capacity. The product division, comprising the sale of medicinal products for medical aesthetics, is in the process of obtaining the manufacturing license. M1 Aesthetics GmbH plans to market medicinal products as manufacturer henceforward. In the Ruhr area the next M1-location will be established in 2015. The value added in the real-estate tenure business will be developed in the Healthcare Real Estate segment. For the optimisation of the liabilities side as well as of the financing of further dynamic growth, MPH AG has successfully issued at short notice two more bonded loans totalling EUR 10,000,000.00. About MPH Mittelständische Pharma Holding AG: Medicines, services for individual patient therapies, aesthetic surgeries and other medical treatments are offered along the value-added-chain in the healthcare market. The MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open Market) on the Frankfurt stock exchange. Details for the share of MPH Mittelständische Pharma Holding AG: 2015-05-29 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MPH Mittelständische Pharma Holding AG | |
Fasanenstraße 77 | ||
10623 Berlin | ||
Germany | ||
Phone: | 030 / 897 308 660 | |
Fax: | 030 / 897 308 669 | |
E-mail: | info@mph-ag.de | |
Internet: | www.mph-ag.de | |
ISIN: | DE000A0L1H32 | |
WKN: | A0L1H3 | |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt | |
End of News | DGAP News-Service |
363221 2015-05-29 |